|Articles|September 13, 2017
Should the Availability of High-Dose Opioids Be Reduced?
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Advertisement
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
RSV Hospitalization Associated With Persistent Symptoms and Reduced Quality of Life in Adults
2
Study Links Specific Air Pollution Components to Increased Depression Risk in Older Adults
3
FLEX Study Data Highlight Role of Genomic Testing in Guiding Early-Stage Breast Cancer Treatment
4
December 2025 Product Updates
5